GT
CTXR icon

Glenmede Trust’s Citius Pharmaceuticals CTXR Stock Holding History

Glenmede Trust’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-80
Closed -$2K – 1456
2020
Q3 		$2K Hold
80
– – ﹤0.01% 2253
2020
Q2 		$2K Buy
+80
New +$1.75K ﹤0.01% 2226

Other funds holding CTXR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WAS
Wealth Advisory Solutions Indiianapolis, Indiana $449M AUM 16.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
MIM
Miller Investment Management West Conshohocken, Pennsylvania $1.01B AUM 13.96% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Glenmede Trust's CTXR Position: Q4 2020 in Review

Glenmede Trust sold out of Citius Pharmaceuticals (CTXR) in Q4 2020, closing a stake of 80 shares — an estimated $2K sold.

Glenmede Trust first reported a position in CTXR in Q2 2020 and held it in 2 quarters. The position peaked at $2K in Q3 2020. 22 funds tracked by Wall St. Rank hold CTXR as of Q4 2020.

  • Glenmede Trust reported no remaining Citius Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Glenmede Trust sold 80 Citius Pharmaceuticals shares in Q4 2020, an estimated $2K.
  • Glenmede Trust first reported a position in Citius Pharmaceuticals in Q2 2020 and held it in 2 quarters.
  • Glenmede Trust's Citius Pharmaceuticals position peaked at $2K in Q3 2020.
  • 22 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.